Key Takeaways
- BSX shares declined 9% to close at $62.93, marking the lowest price point since January 2024
- CHAMPION-AF trial results for Watchman FLX demonstrated non-inferiority compared to anticoagulant therapy, while revealing an ischemic stroke incidence of 3.2% versus 2%
- Raymond James lowered its BSX rating from Strong Buy to Outperform and reduced the price objective from $97 to $88
- The rating adjustment reflected decelerating expansion in U.S. electrophysiology and Watchman segments, which previously contributed more than half of the company’s annual growth
- Year-to-date performance shows BSX down 34%, while the S&P 500 has declined 7.1%
Boston Scientific experienced a challenging trading session on Monday. Shares retreated 9% following dual catalysts: clinical trial findings that failed to meet investor expectations and an analyst rating adjustment from Raymond James.
Boston Scientific Corporation, BSX
The CHAMPION-AF study outcomes for the Watchman FLX device were unveiled at a medical conference on March 30. From a technical standpoint, the results appeared favorable. The device achieved non-inferiority status when compared to contemporary anticoagulants such as Eliquis and Xarelto. Patients using Watchman also experienced decreased non-procedural bleeding risk, successfully meeting the trial’s primary objective.
Market participants, however, focused intensely on a specific metric. The device group experienced a 3.2% ischemic stroke rate, while the anticoagulant cohort showed 2%. This differential, despite its modest size, triggered significant market concern.
The variance lacked statistical significance and fell outside the study’s primary endpoints. Investigators intend to monitor participants for five years to obtain comprehensive stroke risk data.
Clinical Leaders Defend Study Results
Study co-chair Marty Leon characterized the findings as “a very strong endorsement” for broader device utilization. He outlined the benefit-risk profile explicitly: a 0.33% annualized elevation in stroke or embolization against approximately 2.6% reduction in bleeding events. Boston Scientific’s chief medical officer, Ken Stein, supported this interpretation, emphasizing that stroke incidence in both cohorts remained “incredibly low.”
Truist Securities observed that overall conference sentiment proved positive. Leerink Partners indicated that direct interactions at the event strengthened their confidence that trial outcomes would drive increased Watchman procedure volumes moving forward.
Despite these perspectives, market reaction remained negative. BSX settled at $62.93, representing the weakest close since January 30, 2024.
Concurrently, Raymond James revised its BSX rating from Strong Buy to Outperform while lowering the price objective from $97 to $88. The firm highlighted weakening momentum in two of BSX’s primary growth drivers: U.S. electrophysiology and Watchman, which collectively represented 26% of 2025 revenue and generated over half of the company’s year-over-year expansion.
Raymond James Maintains Positive Outlook While Adjusting Projections
Raymond James analyst Jayson Bedford clarified that the rating change reflected reduced near-term certainty rather than fundamental concerns. The firm continues to regard Boston Scientific as among the highest-quality, fastest-growing enterprises in large-cap medical technology.
The firm lowered its 2026 and 2027 revenue projections by approximately 0.5% and 1.5%. Current models anticipate Watchman growth at 17% and 16% over the next two years, revised from previous estimates of 18% and 20%. EP growth expectations declined to 15% and 14%.
Notwithstanding these adjustments, Raymond James maintains the valuation remains compelling. BSX currently trades at approximately 18 times projected 2027 earnings, compared to 21 times for industry peers.
Multiple other firms — including Bernstein, Evercore ISI, Stifel, Truist, and Jefferies — continue to maintain Buy or Outperform ratings, with price objectives spanning $88 to $120.
BSX has declined 34% year-to-date. The stock reached a 52-week peak of $110 earlier this year.
